Invesco Pharmaceuticals ETF

PJP

Market cap $326M

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

The Invesco Pharmaceuticals ETF (PJP) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Healthcare providers and pharmaceuticals are the most compelling subsectors based on value and quality scores. PJP delivers attractive historical risk-adjusted returns compared to XLV and XPH. 10 healthcare stocks cheaper than their peers in December.

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

The price cuts will save Medicare billions of dollars in prescription-drug spending.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on June 23, 2005.

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.